Sermorelin
GHRH 1-29 Analog (Geref)
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Sermorelin once carried real FDA-approved human evidence for one narrow purpose, pediatric growth hormone deficiency diagnosis and short-term treatment, where controlled trials showed accelerated growth velocity (Prakash and Goa review, Drugs 2008). That approval belonged to Geref and was voluntarily discontinued by EMD Serono in 2008 for commercial reasons, which the FDA formally determined were not related to safety or effectiveness. The current marketed use, adult anti-aging and GH optimization through compounding pharmacies, is off-label and unapproved and rests on preliminary and observational human data rather than adult RCTs, so the grade for the marketed use is 2.
- FDA
- Geref (sermorelin acetate) was FDA-approved in 1997 for pediatric growth hormone deficiency; the manufacturer EMD Serono voluntarily discontinued it in 2008 and requested withdrawal of NDA 20-443 for commercial, not safety, reasons. No FDA-approved sermorelin product exists today; all current use is off-label via compounding pharmacies.
- WADA
- Prohibited at all times under S2.2 (peptide hormones, growth factors, related substances and mimetics), as a growth hormone releasing hormone analog.
Reference only. Not medical advice.
What can go wrong
No FDA-approved product; adult use is off-label and compounded (not FDA-reviewed for quality or efficacy); WADA-prohibited; raises GH and IGF-1; injection-site reactions and flushing reported.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Sermorelin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
A synthetic analog of the first 29 amino acids of growth hormone releasing hormone, marketed as Geref and FDA-approved in 1997 for pediatric growth hormone deficiency. Its manufacturer withdrew it from the US market in 2008 for commercial reasons, a decision the FDA determined was not related to safety or effectiveness. It is now available only through compounding pharmacies, where adult use for growth hormone optimization and anti-aging is off-label and unapproved.
FDA-approved analog whose approval lapsed for commercial reasons. The conservative entry to GH work.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Sermorelin imitates the brain’s growth-hormone-releasing hormone (GHRH). It binds GHRH receptors on the pituitary and tells the gland to make and release the body’s own growth hormone, which then drives IGF-1 and the downstream effects people associate with growth hormone: tissue repair, fat metabolism and protein synthesis. Because it acts on the natural upstream signal, it preserves the body’s pulsing release pattern and its feedback controls, rather than flooding the system the way injected growth hormone does. As GHRH output falls with age, sermorelin tops up that signal.
Sermorelin is a synthetic analog of GHRH. Natural GHRH is 44 amino acids long, and sermorelin is the first 29 of them, the biologically active portion that is enough to trigger the full growth-hormone-release cascade. It is short-acting, and it is the older, foundational GHRH analog, with the longer-acting CJC-1295 being the modern evolution of the same idea.
- Type
- GHRH(1-29) analog
- Action
- Stimulates own GH
- Duration
- Short-acting
- History
- FDA-approved, withdrawn 2008
- Now
- Compounded, off-label
- WADA
- Prohibited (S2)
Once Approved, Withdrawn For Business, Not Failure
Sermorelin stands apart from the gray-market peptides because it has a genuine pharmaceutical history. It was FDA-approved in the 1990s, as Geref, for diagnosing and later treating childhood growth hormone deficiency, on the basis of real peer-reviewed trials showing meaningful growth in responsive children. The honest and important detail is why it lost that status: the brand was withdrawn in 2008 for commercial reasons, a small diagnostic market and competition, not because of any safety or efficacy failure. So today there is no FDA-approved sermorelin product, and all sermorelin is legally compounded through 503A or 503B pharmacies for off-label adult use, mostly anti-aging and growth-hormone optimization. The mechanism is well-characterized and backed by decades of safety data, but for the popular adult anti-aging use specifically, the clinical-benefit evidence is mid-tier rather than definitive. It is banned in sport.
Safety in detail
Because Geref was withdrawn from the US market in 2008, every adult dose today comes from a compounding pharmacy, and compounded preparations are not reviewed by the FDA for safety, potency, or purity. The withdrawal was a commercial decision, and the FDA determined it was not for reasons of safety or effectiveness, so the historical safety record for the pediatric diagnostic indication remains relevant, but adult anti-aging use stays unapproved and off-label.
- It has a well-documented safety profile from decades of clinical use, with mild effects like injection-site reactions, flushing and headache.
- It is more physiologic than direct growth hormone, preserving the body’s feedback and pulsatile release, which makes it harder to overdose.
- The general cautions of raising growth hormone apply, but in milder form than with injected GH.
- Quality varies by source: FDA-registered 503B outsourcing facilities provide inspected, potency-tested product, while 503A and gray-market sources are less controlled.
- It is banned in sport, and its adult anti-aging use is off-label rather than formally approved.
Children and teenagers
Sermorelin’s original approved use was pediatric: diagnosing and treating childhood growth hormone deficiency and short stature, under pediatric endocrinology, a genuine evidence-based medical context. That is entirely separate from the popular off-label adult anti-aging use, which has no pediatric application, and from any gray-market use in healthy minors, which has no place. Any pediatric growth-hormone therapy belongs strictly with pediatric endocrinologists.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Sermorelin’s economy is a largely legitimate clinical one: compounding pharmacies, both 503A and 503B, and the age-management, anti-aging and regenerative-medicine clinics that have made it one of the most prescribed peptides in that space. Its original brand, Geref, was discontinued by its manufacturer. Unlike the gray-market peptides, its money flows mostly through licensed prescribers and regulated compounders, though clinic marketing can still outrun the evidence for its anti-aging benefits.
How we got here
Sermorelin is the 29-amino-acid N-terminal fragment of growth-hormone-releasing hormone (GHRH), the shortest sequence that retains the parent hormone's full biological activity in stimulating pituitary growth hormone release. Marketed as Geref by EMD Serono, it was the first GHRH analog to win FDA approval before both formulations were discontinued in 2008 for commercial rather than safety reasons. The molecule remains widely available today through compounding pharmacies, where it is used off-label for anti-aging and growth-hormone-optimization protocols.
Sermorelin, the active 29-amino-acid fragment of GHRH, was developed and won FDA approval in the 1990s as Geref for diagnosing and treating childhood growth hormone deficiency, supported by real pediatric trials. In 2008 its manufacturer withdrew the brand for commercial reasons, not safety, leaving the molecule without an approved product but with an intact legal compounding pathway. Clinicians and compounding pharmacies then adopted it widely for off-label adult anti-aging and growth-hormone optimization, where it became one of the most prescribed peptides in regenerative medicine, while the longer-acting CJC-1295 emerged as a modern GHRH alternative.
- 1990sFDA approves sermorelin (Geref) for pediatric growth hormone deficiency diagnosis and treatment.
- 1990s-2000sUsed clinically, with peer-reviewed pediatric trial support.
- 2008EMD Serono withdraws Geref for commercial reasons, leaving no approved product.
- 2010s-2020sAdopted widely as a compounded, off-label adult anti-aging and GH-optimization peptide.
- 2026Available only as compounded material, sourced best from 503B facilities.
The numbers behind the grade
- Type
- GHRH(1-29) analog
- History
- FDA-approved 1990s
- Withdrawn
- 2008 (commercial)
- Now
- Compounded, off-label
- Adult evidence
- Mid-tier
- WADA
- Prohibited (S2)
The people taking it
One of the most-prescribed peptides in anti-aging and regenerative medicine, with a real if lapsed FDA history, used off-label for adult growth-hormone optimization and distinct from the gray-market research peptides.
Sermorelin’s users today are overwhelmingly adults with age-related growth-hormone decline, using it through age-management and anti-aging clinics for body composition, recovery, sleep and energy, along with growth-hormone-optimization and wellness seekers. Historically its approved population was children with growth hormone deficiency. It draws a longevity- and performance-minded but largely clinic-based, prescription-driven audience.
Historically approved for pediatric growth hormone deficiency, now compounded for off-label adult anti-aging and growth-hormone optimization. Sound mechanism and decades of safety data, with moderate adult-benefit evidence.
Set against the alternatives
Against direct growth hormone (somatropin), sermorelin is the gentler, more physiologic alternative: it stimulates the body’s own GH with feedback intact, milder and safer but less potent, best suited to mild deficiency or aging where some natural production remains. Against CJC-1295, sermorelin is the older, shorter-acting version of the same GHRH approach, with CJC-1295 offering longer duration. Against the GHRP-class secretagogues like GHRP-6 and ipamorelin, it works through a different, complementary receptor and is often stacked with them. And against the gray-market research peptides, its real pharmaceutical history, legal compounding pathway and decades of safety data set it clearly apart. Its strength is legitimacy and a sound mechanism; its limitation is that the adult anti-aging payoff is only moderately evidenced.
What we do not know
- Whether the adult anti-aging and longevity benefits are clinically meaningful, given mid-tier evidence.
- Whether a new branded therapeutic approval will ever come, given cheap compounded availability.
- How it best fits alongside CJC-1295 and GHRP-class secretagogues.
- What the long-term outcomes of sustained adult use are.
What could change
Anti-aging evidenceThe key open question is whether adult longevity benefits are clinically meaningful.Quality sourcingGrowing emphasis on FDA-registered 503B compounding for reliable product.GHRH stacksContinued use alongside CJC-1295 and GHRP-class secretagogues.Regulatory landscapeIts standing depends on the stability of the compounding pathway.
Legal status
Sermorelin was FDA-approved as Geref in the 1990s for pediatric growth hormone deficiency but was withdrawn in 2008 for commercial reasons, so no FDA-approved product exists today. It remains legally available by prescription through compounding pharmacies, 503A and 503B, for off-label adult use. It is banned in sport, and 503B-sourced product is the higher-quality option.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Sermorelin is obtained legally by prescription through compounding pharmacies, ideally FDA-registered 503B facilities for quality, a legitimate clinical pathway that distinguishes it from gray-market research peptides. For adult anti-aging use, buyers should understand the mechanism is sound but the outcome evidence is mid-tier, and that it is banned in sport.
Compounded sermorelin is moderately priced and usually obtained through clinics. Gray-market material is cheaper but quality-variable. The cost reflects a legitimate compounded medicine rather than an approved branded drug.
The best source is an FDA-registered 503B outsourcing facility, which is inspected and potency-tested; 503A compounders are acceptable but more variable, and research or gray-market material is the least controlled. Source quality matters more here than with most peptides because a legitimate pathway exists.
503B outsourcing facilitiesFDA-registered, inspected and potency-tested, the highest-quality compounded source.503A compounding pharmaciesPatient-specific compounders operating under state pharmacy oversight, quality more variable.Research and gray-marketLower-quality material outside the clinical pathway.
At a glance
- Original brand
- Geref
- Approval
- Lapsed 2008 (commercial)
- Class
- GHRH 1-29 analog
- Now
- Widely compounded
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Sermorelin.
Nothing outstanding on this one.
Sources
FDA formally determined Geref (sermorelin acetate) was not withdrawn from sale for reasons of safety or effectiveness; EMD Serono notified FDA of discontinuation in letters dated July 11 and December 2, 2008, and requested withdrawal of NDA 20-443.
Sermorelin was FDA-approved in 1997 as Geref for pediatric growth hormone deficiency and as a diagnostic agent for GH secretion; discontinued in 2008 for commercial reasons; mechanism is GHRH 1-29 analog.
Peer-reviewed review of sermorelin use in the diagnosis and treatment of children with idiopathic growth hormone deficiency, documenting controlled evidence for growth velocity in the pediatric indication.
WADA Prohibited List classifies GHRH analogs including sermorelin, CJC-1295, and tesamorelin under S2 (peptide hormones, growth factors, related substances and mimetics), prohibited at all times.
Analytical characterization of GHRH synthetic analogs (including sermorelin) and their metabolites for anti-doping detection, confirming their status as monitored prohibited substances.
Review of growth hormone secretagogues, including GHRH analogs like sermorelin, in the modern management of body composition in hypogonadal males, framing adult use as investigational and off-label.
Sermorelin holds no active FDA approval; all current adult use is off-label through compounding pharmacies under FDCA Sections 503A and 503B, and compounded products are not FDA-reviewed for safety, quality, or efficacy.
Sermorelin is not a controlled substance; adult anti-aging use in healthy older adults remains unproven and is not an FDA-approved indication; Geref was discontinued in 2008 for commercial reasons.
Innerbody, Sermorelin Peptide Benefits, Safety, and Buying Advice
Empower Pharmacy compounded sermorelin acetate injection product information, documenting that sermorelin is currently supplied to adults as a compounded preparation.
The studies that matter
Pediatric approval trials1990s
Peer-reviewed trials supported FDA approval of sermorelin (Geref) for diagnosing and treating childhood growth hormone deficiency, including idiopathic short stature.
Height-velocity data1990s
Daily sermorelin produced meaningful increases in growth rate in responsive children, with smaller effects than direct growth hormone but a milder side-effect profile.
Commercial withdrawal2008
EMD Serono withdrew Geref from the US market for commercial reasons, not safety or efficacy, leaving no approved product.
Adult anti-aging use2010s-2020s
Used in age-management clinics for declining growth hormone, where the mechanism is plausible but clinical-benefit evidence is limited.
Decades of safety dataongoing
Long clinical use has produced a well-documented safety profile, distinguishing it from unapproved research peptides.